This article provides insufficient context for those unfamiliar with the subject. Please help improve the article by providing more context for the reader. (March 2021) (Learn how and when to remove this template message)
TC-2216
TC-2216.svg
Identifiers
  • 8-pyridin-3-yl-1,8-diazaspiro[4.4]nonane
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H17N3
Molar mass203.283 g·mol−1
3D model (JSmol)
  • N1CCCC1(CC2)CN2c3cnccc3
  • InChI=1S/C12H17N3/c1-3-11(9-13-6-1)15-8-5-12(10-15)4-2-7-14-12/h1,3,6,9,14H,2,4-5,7-8,10H2
  • Key:NXIPMBQVNTWEEX-UHFFFAOYSA-N
  (verify)

TC-2216 is a drug developed by Targacept which acts as a partial agonist at neural nicotinic acetylcholine receptors and was researched for the treatment of anxiety and depression.[1] It was unsuccessful as a therapeutic but is still used in pharmacological research as an alpha4beta2-selective antagonist.[2]

References

  1. ^ Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F (June 2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–67. doi:10.1002/cmdc.200600207. PMID 17295372. S2CID 34763474.
  2. ^ Lippiello PM, Beaver JS, Gatto GJ, James JW, Jordan KG, Traina VM, Xie J, Bencherif M (2008). "TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity". CNS Neuroscience & Therapeutics. 14 (4): 266–77. doi:10.1111/j.1755-5949.2008.00054.x. PMC 6494058. PMID 19040552.